암 치료의 감염 관리 시장 규모 : 제품 유형별, 용도별, 최종 사용자별, 지역별, 예측별, 지역별 시장 규모

Infection Control in Cancer Therapy Market Overview

The infection control in cancer therapy market is expanding steadily, driven by the rising prevalence of immunocompromised patients and the critical need to prevent hospital-acquired infections during chemotherapy and radiotherapy. Adoption is increasing as healthcare facilities implement advanced sterilization techniques, antimicrobial coatings, and infection monitoring systems to safeguard vulnerable cancer patients.

Demand is supported by the growing incidence of cancer, the increasing complexity of treatment protocols, and regulatory emphasis on patient safety and hygiene standards in oncology wards. Market momentum is shaped by ongoing innovations in sterilization technologies, diagnostic infection monitoring, and antimicrobial surface solutions, which are enhancing protection across clinical settings while supporting improved patient outcomes and operational efficiency.

Market size - VMR Analyst Corridor Approach

A revenue convergence corridor is emerging across recent global assessments instead of relying on a single-point estimate. Market value is consolidating around USD 3.74 Billion in 2025, while long-term projections are extending toward USD 6.33 Billion in 2033, reflecting mid- to high-single-digit growth momentum. A CAGR of 6.8% is being recorded over the forecast period (2027-2033), underscoring the market's structurally resilient growth trajectory

Global Infection Control in Cancer Therapy Market Definition

The infection control in cancer therapy market encompasses the development, production, distribution, and deployment of solutions, technologies, and protocols aimed at preventing, monitoring, and managing infections among patients undergoing cancer treatments, including chemotherapy, radiotherapy, and immunotherapy. Product scope includes antimicrobial drugs, infection prevention devices, sterilization systems, personal protective equipment (PPE), and diagnostic and monitoring tools designed for clinical and outpatient oncology settings.

Market activity spans pharmaceutical manufacturers, medical device producers, healthcare technology providers, and service integrators serving hospitals, cancer treatment centers, outpatient clinics, and research institutions. Demand is driven by patient susceptibility, treatment-induced immunosuppression, hospital-acquired infection rates, regulatory compliance requirements, and the need for safe, uninterrupted therapy. Sales channels include direct hospital procurement, distributor networks, and contract agreements with oncology service providers, ensuring long-term infection control adherence and operational continuity.

Global Infection Control in Cancer Therapy Market Drivers

The market drivers for the infection control in cancer therapy market can be influenced by various factors. These may include:

High Demand for Enhanced Infection Control Protocols in Oncology Units

Increasing focus on infection prevention in oncology units is driving the market, as immunocompromised cancer patients are highly vulnerable to healthcare-associated infections (HAIs). Globally, around 10% of patients in healthcare settings acquire an HAI, with rates reaching 15% in low- and middle-income countries and about 7% in high-income regions. Advanced sterilization and hygiene systems strengthen procedural reliability, reducing infection risks and ensuring safer cancer treatment outcomes.

Adoption of Advanced Disinfection and Sterilization Technologies

The growing use of sophisticated sterilization and disinfection technologies is fueling market demand, as precise pathogen control is critical during intensive cancer therapies. Studies suggest that a significant portion of HAIs can be prevented through effective infection prevention and control (IPC) practices. Automated sterilization systems deliver consistent pathogen reduction while maintaining the integrity of sensitive oncology treatment environments.

Integration of Surveillance Systems and Data-Driven Monitoring

The integration of real-time infection surveillance and data-driven monitoring platforms is accelerating market growth. These tools enable early detection and proactive management of infection risks in cancer therapy units. With antimicrobial resistance contributing to an estimated 136 million antibiotic-resistant HAIs annually, oncology centers are increasingly relying on analytics-driven monitoring to improve patient safety and minimize complications.

Investment in Patient Safety Initiatives and IPC Programs

Rising investments in patient safety initiatives and structured IPC programs are supporting market expansion. While many healthcare systems have IPC programs in place, only a small fraction fully meet global standards, highlighting the need for continuous resource allocation, staff training, and deployment of best-practice protocols to protect patients undergoing cancer therapies. This focus on robust infection control not only improves patient outcomes but also reduces treatment delays and associated healthcare costs.

Global Infection Control in Cancer Therapy Market Restraints

Several factors act as restraints or challenges for the infection control in cancer therapy market. These may include:

High Treatment and Operational Costs

High treatment and operational costs are restraining broader adoption, as advanced infection control protocols require specialized equipment, sterilization technologies, and continuous monitoring systems. Healthcare facilities, particularly in cost-sensitive regions, face budgetary pressures where reimbursement models may not fully cover preventive measures. Supplier pricing reflects the need for high-quality materials and regulatory compliance, limiting widespread scalability.

Stringent Regulatory and Compliance Requirements

Stringent regulatory and compliance requirements limit deployment, as infection control products and procedures must adhere to multiple national and international standards. Approval timelines are prolonged due to rigorous clinical validation, documentation, and certification processes. Non-compliance carries severe financial and legal implications, increasing the overall risk and operational oversight required by healthcare institutions.

Limited Awareness and Training Among Healthcare Professionals

Limited awareness and training among healthcare professionals restrict adoption, as proper infection control in oncology settings requires specialized knowledge and adherence to strict procedural protocols. Workforce readiness remains uneven across hospitals, particularly in emerging markets. Training programs require additional investment in both time and resources, beyond the cost of implementing control measures.

Integration Challenges with Existing Hospital Infrastructure

Integration challenges with existing hospital infrastructure act as a barrier, as infection control solutions must be compatible with established clinical workflows, HVAC systems, and patient management protocols. Customization is often required to fit varying hospital layouts and technology ecosystems. Interoperability issues prolong implementation timelines and increase operational complexity for healthcare providers.

Global Infection Control in Cancer Therapy Market Opportunities

The landscape of opportunities within the infection control in cancer therapy market is driven by several growth-oriented factors and shifting global demands. These may include:

Adoption of Advanced Sterilization and Disinfection Technologies

Growing adoption of advanced sterilization and disinfection technologies is creating strong opportunities for the infection control in cancer therapy market, as precise microbial elimination reduces healthcare-associated infections (HAIs) among immunocompromised patients. Automated surface and air sterilization systems, as well as UV and hydrogen-peroxide-based solutions, are increasingly specified in oncology wards. Capital expenditure allocation toward next-generation IPC platforms is therefore favoring deployment of these advanced infection control solutions.

Integration of Infection Surveillance and Data-Driven Monitoring

Rising integration of infection surveillance and data-driven monitoring solutions is generating new growth avenues, as real-time tracking and analytics enhance early detection and proactive management of infection risks. Predictive algorithms and electronic reporting improve patient safety and operational efficiency. Adoption of digital IPC platforms is therefore accelerating in cancer care units.

Expansion in Oncology Patient Safety Programs

Increasing investment in oncology patient safety programs is supporting market expansion, as structured infection control initiatives help reduce morbidity and treatment delays. Risk mitigation measures, staff training, and compliance monitoring strengthen procedural consistency and clinical outcomes. Hospital and healthcare system procurement decisions are increasingly aligned with comprehensive IPC programs.

Opportunities in Immunocompromised Patient Care Services

High potential exists in expanding infection control services specifically tailored to immunocompromised cancer patients, as targeted interventions reduce complications and improve treatment continuity. Personalized IPC solutions, including portable sterilization units and patient-specific isolation protocols, enhance care delivery. Growing demand for safer outpatient and home-based cancer therapies is increasing adoption of these solutions.

Global Infection Control in Cancer Therapy Market Segmentation Analysis

The Global Infection Control in Cancer Therapy Market is segmented based on Product Type, Application, End-User, and Geography.

Infection Control in Cancer Therapy Market, By Product Type

Disinfectants: Disinfectants hold a dominant share in the infection control market, as high efficacy against pathogens, rapid action, and compatibility with medical surfaces support widespread adoption across hospitals, specialty clinics, and research facilities. Rising focus on patient safety and nosocomial infection prevention is driving adoption in oncology settings. Emerging demand for environmentally safe and non-toxic disinfectants is expected to fuel future growth, supported by regulatory compliance and hospital procurement standards.

Sterilization Equipment: Sterilization equipment is witnessing substantial growth, as advanced autoclaves, UV sterilizers, and plasma systems provide reliable decontamination for medical instruments, protective gear, and clinical spaces. Increased utilization in chemotherapy, radiation therapy, and immunotherapy procedures is boosting demand, with technological enhancements in efficiency, compact design, and automation driving adoption. Continuous improvements in throughput and operational reliability position this segment for sustained expansion.

Protective Apparel: Protective apparel is experiencing significant traction, as gowns, gloves, masks, and full-body suits ensure contamination control and safeguard healthcare personnel. Heightened awareness of cross-infection risks in cancer therapy settings is encouraging adoption across hospitals and specialty clinics. Innovations in comfort, durability, and barrier properties are further supporting growth, while regulatory mandates and staff safety protocols reinforce procurement patterns.

Infection Control in Cancer Therapy Market, By Application

Chemotherapy: Chemotherapy applications are driving demand for infection control solutions, as immunocompromised patients are highly susceptible to infections. Adoption of stringent sterilization protocols, disinfectants, and personal protective equipment (PPE) is increasing across oncology wards and outpatient infusion centers. Rising incidence of cancer globally and focus on patient safety measures are boosting market adoption in chemotherapy workflows.

Radiation Therapy: Radiation therapy applications are on an upward trajectory, as precise infection control is critical during patient preparation, equipment handling, and post-treatment recovery. Integration of disinfectants, sterilization systems, and protective apparel ensures minimal microbial contamination and improved procedural safety. Technological advancements in sterilization equipment compatible with radiology environments are supporting segment growth.

Immunotherapy: Immunotherapy applications are experiencing growth in infection control adoption, as highly targeted therapies require ultra-clean environments to prevent opportunistic infections. Use of advanced sterilization systems, disinfectants, and specialized protective apparel is increasing in cancer research institutes and clinical trial facilities. Rising focus on patient outcomes, immunocompromised care, and regulatory compliance is propelling segment expansion.

Infection Control in Cancer Therapy Market, By End-User

Hospitals: Hospitals account for the largest share in the infection control market, as high patient volume, oncology wards, and procedural diversity necessitate robust infection prevention protocols. Adoption of comprehensive disinfectant systems, sterilization equipment, and protective apparel ensures compliance with healthcare regulations and enhances patient safety. Growth is supported by rising cancer prevalence, hospital expansions, and focus on operational efficiency.

Cancer Research Institutes: Cancer research institutes are increasingly deploying infection control solutions, as laboratory safety, sterile environments, and experimental integrity are critical. Advanced sterilization equipment, disinfectants, and specialized PPE are essential for handling patient samples, cell cultures, and immunotherapy research. Growing investment in oncology R&D and regulatory mandates for lab safety are driving market momentum.

Specialty Clinics: Specialty clinics are gaining traction in infection control adoption, as outpatient chemotherapy, immunotherapy, and radiation therapy services require targeted infection prevention measures. Use of disinfectants, compact sterilization units, and protective apparel ensures safe patient care and staff protection. Expansion of outpatient oncology services and patient-centric care models supports segment growth.

Infection Control in Cancer Therapy Market, By Geography

North America: North America is witnessing significant growth in the infection control in cancer therapy market, driven by advanced oncology centers, high prevalence of cancer, and strong healthcare infrastructure in states such as California, Texas, and Massachusetts. Increasing investment in sterile equipment, antimicrobial therapies, and hospital infection control programs is boosting regional demand. Rising adoption of targeted cancer therapies and immunocompromised patient care protocols is enhancing market penetration.

Europe: Europe is observing steady expansion in the infection control in cancer therapy market, with countries including Germany, France, and the United Kingdom leading growth due to well-established healthcare systems and advanced cancer treatment facilities. Emphasis on infection prevention protocols, hospital hygiene, and patient safety in cities such as Munich, Paris, and London is driving adoption. Focus on innovative sterilization technologies and antibiotic stewardship programs supports widespread integration.

Asia Pacific: Asia Pacific is on a rising trajectory in the infection control in cancer therapy market, as rapidly growing oncology centers, research hospitals, and healthcare infrastructure in China, Japan, South Korea, and Australia are increasing adoption. Urban hubs such as Shanghai, Tokyo, Seoul, and Sydney are witnessing higher demand for infection prevention solutions due to the expansion of chemotherapy, radiotherapy, and surgical oncology services. Heightened attention to patient safety, antimicrobial coatings, and hospital-acquired infection reduction is reinforcing sustained regional growth.

Latin America: Latin America is experiencing notable growth in the infection control in cancer therapy market, with countries such as Brazil, Mexico, and Argentina increasing adoption for oncology care, hospital hygiene, and clinical research applications. Cities such as Sao Paulo, Mexico City, and Buenos Aires are seeing rising investment in sterile technologies, antimicrobial solutions, and infection monitoring systems. Government initiatives to improve hospital safety and support oncology infrastructure are driving market penetration.

Middle East and Africa: The Middle East and Africa are poised for expansion in the infection control in cancer therapy market, as healthcare centers, cancer institutes, and research facilities in the United Arab Emirates, South Africa, and Egypt adopt advanced infection prevention protocols. Increased use of sterilization equipment, antimicrobial therapies, and patient monitoring systems is fueling regional growth. Strategic investment in hospital infrastructure and infection control initiatives is supporting long-term development across both Middle Eastern and African markets.

Key Players

• The competitive environment is remaining brand-driven, with established players leveraging distribution scale, product breadth, and brand trust. Competitive differentiation is shifting toward material transparency, comfort-led design, and sustainability positioning, while portfolio consolidation and brand acquisition activity are reshaping ownership dynamics.
• Key Players Operating in the Global Infection Control in Cancer Therapy Market

3M Company

• Steris Corporation
• Getinge AB
• Advanced Sterilization Products Services, Inc.
• Belimed AG
• Cantel Medical Corporation
• Matachana Group
• Ecolab Inc.
• Sotera Health Company
• Metrex Research, LLC
• Cardinal Health, Inc.
• Olympus Corporation
• Halyard Health, Inc.
• Market Outlook and Strategic Implications
• Growth momentum is remaining stable, while strategic focus is increasingly prioritizing compliance readiness, premiumization, and consumer trust reinforcement. Investment allocation is shifting toward scalable innovation and lifecycle value, as transparency, safety assurance, and access expansion are emerging as long-term competitive differentiators.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA AGE GROUPS

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET OVERVIEW
• 3.2 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ATTRACTIVENESS ANALYSIS, BY PRODUCT TYPE
• 3.8 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.9 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.10 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET , BY PRODUCT TYPE (USD BILLION)
• 3.12 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET , BY APPLICATION (USD BILLION)
• 3.13 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET , BY END-USER(USD BILLION)
• 3.14 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET , BY GEOGRAPHY (USD BILLION)
• 3.15 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET EVOLUTION
• 4.2 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE GENDERS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY PRODUCT TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET : BASIS POINT SHARE (BPS) ANALYSIS, BY PRODUCT TYPE
• 5.3 DISINFECTANTS
• 5.4 STERILIZATION EQUIPMENT
• 5.5 PROTECTIVE APPAREL

6 MARKET, BY APPLICATION

• 6.1 OVERVIEW
• 6.2 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET : BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 6.3 CHEMOTHERAPY
• 6.4 RADIATION THERAPY
• 6.5 IMMUNOTHERAPY

7 MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 GLOBAL INFECTION CONTROL IN CANCER THERAPY MARKET : BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER
• 7.3 HOSPITALS
• 7.4 CANCER RESEARCH INSTITUTES
• 7.5 SPECIALTY CLINICS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 3M COMPANY
• 10.3 STERIS CORPORATION
• 10.4 GETINGE AB
• 10.5 ADVANCED STERILIZATION PRODUCTS SERVICES, INC.
• 10.6 BELIMED AG
• 10.7 CANTEL MEDICAL CORPORATION
• 10.8 MATACHANA GROUP
• 10.9 ECOLAB INC.
• 10.10 SOTERA HEALTH COMPANY
• 10.11 METREX RESEARCH, LLC
• 10.12 CARDINAL HEALTH, INC.
• 10.13 OLYMPUS CORPORATION
• 10.14 HALYARD HEALTH, INC.